-
Mashup Score: 0Biomedicine Lecture Series and Health Equity Research Outreach (BLS-HERO) Joint Event - Contagious Information: Building Trust While Debunking Disinformation - 10 month(s) ago
The Center for Translation Research and Implementation Science (CTRIS) at the National Heart, Lung, and Blood Institute (NHLBI) invites you to join the second session in the 2023 Health Equity Research Outreach (HERO) Quarterly Lecture Series combined with Biomedicine Lecture Series (BLS). We are pleased to have as our speaker, Dr. Seema Yasmin, Director – Stanford Health Communication…
Source: NIH VideoCastingCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Best evidence shows no risk reduction, experts conclude
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
The #HERO trial reported a #cardiovascular benefit with an #antagonist versus an #agonist. But you noted some problems with this study. What were they? #oncology @ASCO #ASCOReadingRoom Read more: https://t.co/PWdbIpJl0F https://t.co/UKP1sF22TA
-
-
Mashup Score: 3
Anti-vaccine harassment cannot stand.
Source: www.nytimes.comCategories: Infectious Disease, Latest HeadlinesTweet-
1/2:"The vaccine disinformation playbook includes the use of fake experts, logical fallacies, impossible expectations, cherry-picked data & conspiracy theories." In the midst of undescrible tragedy, @celinegounder is fighting disinformation. #Hero https://t.co/AKkc9PVZDw
-
-
Mashup Score: 2Army Veteran Went Into ‘Combat Mode’ to Disarm the Club Q Gunman - 1 year(s) ago
Richard M. Fierro, who served for 15 years in the military, was at the nightclub in Colorado Springs with his family when the gunman opened fire. “I just knew I had to take him down,” he said.
Source: www.nytimes.comCategories: Cardiologists, Latest HeadlinesTweet-
Thank you Richard Fierro, for being a hero in so many ways. “These kids want to live that way, want to have a good time, have at it. I’m happy about it because that is what I fought for, so they can do whatever the hell they want.” #hero https://t.co/M7btjqDnph
-
-
Mashup Score: 0A Sarasota County hospital is dealing with a surge in patients after Ian. But help has arrived - 2 year(s) ago
Health workers on a federal disaster relief team have set up a tent emergency room outside Sarasota Memorial Hospital in Venice. They’re helping take the pressure off, so hospital staff can focus on treating the sickest patients.
Source: WUSF Public MediaCategories: Healthcare Professionals, Latest HeadlinesTweet-
So proud to see friend and @Bos_CHIP PharmD colleague @smanzi2 once again heading into the disaster zone with the pediatric Disaster Medial Assistance Team (DMAT). #HERO https://t.co/oymThV9TCl
-
-
Mashup Score: 3
EAU 2022 Bertrand Tombal HERO study, relugolix versus leuprolide in men with advanced prostate cancer relugolix demonstrated more rapid and sustained profound testosterone suppression compared with leuprolide in the phase 3 HERO study
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Sustained castration to 20 ng/dl for relugolix vs. leuprolide in men with advanced #ProstateCancer: results from the phase 3 #HERO study. Presentation by @BertrandTOMBAL @UCLouvain_be. #EAU22 written coverage by @zklaassen_md @GACancerCenter > https://t.co/hDzok76TIH @Uroweb https://t.co/T1GBXvXxD2
-
-
Mashup Score: 1
ASCO 2022 HERO trial, efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer based on baseline body mass index (BMI), relugolix demonstrated greater continuous testosterone suppression than leuprolide regardless of baseline BMI.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Efficacy and safety of relugolix in men with adv #ProstateCancer based on baseline BMI: subgroup analysis from the randomized, phase 3 #HERO study vs leuprolide. Presentation by Fred Saad @chumontreal. #ASCO22 written coverage by @zklaassen_md > https://t.co/1JnFmi8dCQ @PCFnews https://t.co/Zgql64qFav
-
-
Mashup Score: 0Log in or sign up to view - 2 year(s) ago
See posts, photos and more on Facebook.
Source: www.facebook.comCategories: Hematologists1, Latest HeadlinesTweet-
@suleikajaouad I heard you speak at the @AAMCtoday or @ASH_hematology and introduced myself what a #hero you are @MayoHumanities and I believe in the #power of #art to #heal sending you 🙏🏻📿🛐 https://t.co/Fmi1p1hRHD
-
-
Mashup Score: 1John R. Lewis | Institute for Social Justice - 2 year(s) ago
DonateJohn Lewis’ final message to us, as narrated by Morgan Freeman.
Source: jrlinstituteforsocialjustice.orgCategories: Hematologists1, Latest HeadlinesTweet-
A personal #hero @JohnLewisLegacy visit https://t.co/2usVvhgNjQ To make a difference @MayoClinicSOM @MayoGradSchool #DiversityandInclusion #SocialJusticeDay https://t.co/fWXwG6Lyck
-
-
Mashup Score: 7
ASCO GU 2022 HERO trial relugolix in advanced prostate cancer examining for effect modification by patient race, Black men enrolled in the HERO trial, superior continuous suppression of testosterone to castrate levels with relugolix, relugolix HERO a once-daily oral GnRH receptor antagonist compared to leuprolide.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Efficacy and safety of #relugolix in Black men with adv #ProstateCancer: A subgroup analysis from the randomized, phase 3 #HERO study vs leuprolide. Presented by @Daniel_J_George @DukeCancer. #GU22 written coverage by @WallisCJD @UofT > https://t.co/T1EJtpehJj @ASCO https://t.co/hYLV0WY34E
-
.@NIH: Not to be missed: June 21 at 3pm ET. Live Videocast of Dr. Seema Yasmin’s #Biomedicine Lecture "Contagious #Information: Building #Trust While Debunking #Disinformation. #HealthEquity #NHLBI #HERO @NIHCEAL Watch Lecture: https://t.co/1tIR3le5cE https://t.co/XjARNaxgZl